Ovranette

How to order Ovranette

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Ovranette on Prescriptsy

Ovranette is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Ovranette is a combined oral contraceptive (COC) pill containing levonorgestrel 150 micrograms and ethinylestradiol 30 micrograms.

It is one of the most widely prescribed contraceptive pills in the United Kingdom, offering reliable pregnancy prevention when taken correctly.

Each pack contains 21 tablets taken once daily, followed by a 7-day pill-free interval during which a withdrawal bleed occurs.

Ovranette is a prescription-only medicine (POM), manufactured by Pfizer.

Contraception is a cornerstone of reproductive healthcare, enabling individuals and couples to plan if and when to have children.

In the UK, approximately 3.1 million women use a form of hormonal contraception, with the combined pill remaining one of the most popular choices.

The combined oral contraceptive pill was first introduced in the 1960s and has undergone continuous refinement in terms of hormone doses and progestogen types.

Modern low-dose COCs such as Ovranette (containing 30 micrograms of ethinylestradiol) offer effective contraception with a lower risk of side effects compared with earlier higher-dose formulations.

This page provides a comprehensive clinical guide to Ovranette, including how it works, dosage instructions, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about Ovranette

Before reading further, please note these essential safety points.

• Ovranette is not suitable for women who smoke and are aged 35 or over, due to a significantly increased risk of cardiovascular events.
• Do not use Ovranette if you experience migraine with aura, as this increases the risk of stroke.
• All combined pills carry a small increased risk of blood clots (VTE). Seek urgent medical attention if you develop sudden leg pain or swelling, chest pain, or breathlessness.
• Missed pills can reduce effectiveness. Follow the FSRH missed pill rules carefully.
• Certain medicines can reduce the effectiveness of Ovranette, including enzyme-inducing drugs and St John's wort.

Understanding combined oral contraception

Combined oral contraceptives contain a synthetic oestrogen (ethinylestradiol or estradiol valerate) and a synthetic progestogen. The oestrogen and progestogen work together to suppress the hypothalamic-pituitary-ovarian axis.

In a natural menstrual cycle, the hypothalamus releases gonadotrophin-releasing hormone (GnRH), which stimulates the pituitary gland to produce follicle-stimulating hormone (FSH) and luteinising hormone (LH).

FSH promotes follicular development in the ovary, and the mid-cycle LH surge triggers ovulation. The COC suppresses both FSH and LH, preventing follicular maturation and ovulation.

Additionally, the progestogen component thickens the cervical mucus, creating a physical barrier to sperm, and alters the endometrium, making it thinner and less receptive to implantation.

Monophasic COCs such as Ovranette contain the same dose of oestrogen and progestogen in every tablet, making them straightforward to use.

Phasic preparations (biphasic, triphasic) vary the hormone doses through the cycle to mimic physiological fluctuations more closely, but there is no consistent evidence that phasic pills offer clinical advantages over monophasic pills in terms of efficacy, side effects, or cycle control.

What Ovranette contains and how it works

Levonorgestrel is a second-generation progestogen derived from 19-nortestosterone. It has strong progestogenic activity and moderate androgenic activity.

It is one of the best-characterised progestogens in clinical use, with decades of safety data.

Levonorgestrel-containing COCs are associated with the lowest VTE risk among all combined pills, which is why many prescribers choose them as a first-line option, particularly for women starting hormonal contraception for the first time.

Ethinylestradiol is a synthetic oestrogen that is more potent and has a longer half-life than natural estradiol.

At the 30 microgram dose in Ovranette, it provides adequate suppression of ovulation and good cycle control (predictable, regular withdrawal bleeds with minimal breakthrough bleeding).

It is metabolised in the liver via the cytochrome P450 system, which is relevant to drug interactions with enzyme-inducing medicines.

When taken correctly (one tablet daily at the same time for 21 days, followed by a 7-day break), Ovranette is more than 99 percent effective at preventing pregnancy.

The typical-use failure rate is approximately 9 percent per year, reflecting missed pills, vomiting, diarrhoea, and drug interactions.

Taking the pill at the same time each day is the single most important factor in maintaining effectiveness.

Ovranette compared with other contraceptive options

Several combined oral contraceptives are available in the UK. Microgynon 30 contains the same active ingredients as Ovranette (levonorgestrel 150 micrograms, ethinylestradiol 30 micrograms) and is bioequivalent.

Rigevidon is another generic alternative with the same formulation.

Marvelon contains desogestrel (a third-generation progestogen) with ethinylestradiol 30 micrograms, offering less androgenic activity but a slightly higher VTE risk.

Yasmin contains drospirenone with ethinylestradiol 30 micrograms, which has anti-androgenic and anti-mineralocorticoid properties but a higher VTE risk.

Eloine and other ultra-low-dose pills contain ethinylestradiol 20 micrograms, which may cause more breakthrough bleeding but slightly fewer oestrogen-related side effects.

Non-pill alternatives include the contraceptive patch (Evra), the vaginal ring (NuvaRing), progestogen-only pills, the contraceptive implant (Nexplanon), injectable contraception (Depo-Provera, Sayana Press), and intrauterine methods (hormonal IUS such as Mirena, or the copper IUD).

Long-acting reversible contraceptives (LARCs) are recommended by NICE and the FSRH as first-line options because they do not depend on daily adherence and have very low failure rates.

However, the combined pill remains an appropriate and popular choice for women who prefer a user-controlled, easily reversible method with the flexibility to adjust or stop treatment at any time.

Dosage and administration

Take one tablet daily at the same time for 21 consecutive days, then observe a 7-day pill-free break. A withdrawal bleed typically occurs during the break.

Start the next pack on day 8 regardless of bleeding. If starting on day 1 of your period, protection is immediate.

If starting at any other time, use condoms for the first 7 days.

The FSRH now supports flexible regimens, including continuous use (running packs together without a break) or tailored breaks (for example, a 4-day break every 3 weeks instead of a 7-day break every 3 weeks).

These approaches maintain more stable hormone levels, reduce the chance of escape ovulation during the break, and may reduce withdrawal symptoms such as headache, mood changes, and period pain.

Discuss flexible regimens with your prescriber.

If you miss pills, follow the FSRH missed pill guidance. One missed pill (24 to 48 hours late): take it as soon as you remember and continue normally.

Two or more missed pills (48 hours or more late): take the last missed pill, discard earlier missed ones, use condoms for 7 days, and if fewer than 7 pills remain, start the next pack immediately without a break.

If pills were missed in week 1 and unprotected sex occurred, consider emergency contraception.

Side effects of Ovranette

Common side effects

Headache, nausea, breast tenderness, mood changes (low mood, irritability, anxiety), breakthrough bleeding or spotting, weight fluctuation, fluid retention, and reduced libido are commonly reported, particularly during the first 1 to 3 months.

Most of these effects settle as the body adjusts to the hormones. If they persist beyond 3 months, your prescriber may recommend switching to a different pill formulation.

Blood clots

All combined hormonal contraceptives carry a small increased risk of venous thromboembolism (DVT and PE).

For Ovranette (containing levonorgestrel), the risk is approximately 5 to 7 per 10,000 women per year, compared with approximately 2 per 10,000 in non-users.

This is the lowest VTE risk among the combined pills.

Risk factors that increase this risk include obesity (BMI above 30), smoking, immobility, major surgery, family history of VTE, and certain thrombophilic conditions.

Seek emergency medical attention by calling 999 if you develop sudden leg pain, swelling, or warmth, or sudden chest pain, breathlessness, or coughing up blood.

Arterial events and cancer

The risk of myocardial infarction and ischaemic stroke is very slightly increased with COC use, but the absolute risk is very low in young, healthy, non-smoking women.

Smoking over the age of 35 dramatically increases this risk. There is a small increase in breast cancer risk during current COC use, which diminishes after stopping.

Long-term use is associated with a small increase in cervical cancer risk, but COC use reduces the risk of ovarian, endometrial, and colorectal cancer.

When to seek medical advice

Stop Ovranette and seek urgent medical attention if you develop sudden severe headache, visual disturbance, numbness or weakness in the face, arm, or leg, chest pain, breathlessness, sudden leg swelling or pain, or yellowing of the skin or eyes.

Call 999 if symptoms suggest a DVT, PE, stroke, or heart attack.

Contact your GP or NHS 111 for persistent headache, mood changes, breakthrough bleeding lasting more than 3 months, or other concerns.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Who should not take Ovranette

Ovranette is contraindicated in women with current or past VTE, arterial thromboembolic events, known thrombophilia, migraine with aura, uncontrolled hypertension, current breast cancer, severe liver disease, undiagnosed vaginal bleeding, or known pregnancy.

Women who smoke and are aged 35 or over must not use combined hormonal contraception.

Blood pressure and BMI

Blood pressure should be measured before prescribing and at regular intervals. If hypertension develops, an alternative method should be used. Women with a BMI of 35 or above should generally be offered a non-oestrogen-containing method due to elevated VTE risk.

Medicines that reduce effectiveness

Enzyme-inducing medicines (rifampicin, carbamazepine, phenytoin, phenobarbital, St John's wort, and others) accelerate the metabolism of ethinylestradiol and levonorgestrel, significantly reducing contraceptive effectiveness.

Use additional contraception or switch to a method not affected by enzyme inducers. Lamotrigine levels may be reduced by ethinylestradiol; specialist advice is needed if co-prescribing.

Contraception access in the UK

All contraception, including Ovranette, is available free of charge on the NHS, regardless of age or where you live in the UK.

You can obtain a prescription from your GP, a sexual health clinic (also known as a family planning clinic or GUM clinic), a community contraception service, or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

There is no NHS prescription charge for contraceptive medicines in any part of the UK.

Sexual health clinics provide contraception confidentially, including to under-16s who meet the Fraser guidelines criteria for competence.

Sources

• Ovranette, Summary of Product Characteristics (EMC)
• Levonorgestrel with ethinylestradiol, British National Formulary (BNF)
• FSRH: Combined Hormonal Contraception
• Combined pill, NHS
• NICE NG88: Heavy menstrual bleeding (assessment and management)
• MHRA Yellow Card Scheme